NOVACYT (ALNOV.PA) Stock Price, Forecast & Analysis
Europe - EPA:ALNOV - FR0010397232 - Common Stock
ALNOV.PA Key Statistics, Chart & Performance
The current stock price of ALNOV.PA is 0.4355 EUR. In the past month the price decreased by -6.14%. In the past year, price decreased by -27.66%.
ALNOV.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 71.89 | 47.36B | ||
| ARGX.BR | ARGENX SE | 72.88 | 48.01B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.63B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.33B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.33B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.24 | 1.03B | ||
| NANO.PA | NANOBIOTIX | N/A | 876.56M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 494.46M | ||
| FYB.DE | FORMYCON AG | N/A | 366.65M | ||
| VLA.PA | VALNEVA SE | N/A | 332.16M |
Related stock screener links
About ALNOV.PA
Company Profile
Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 234 full-time employees. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. The company offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.
Company Info
NOVACYT
131 Boulevard Carnot, Le Vesinet
Velizy-Villacoublay ILE-DE-FRANCE FR
Employees: 240
Phone: 33139465104
NOVACYT / ALNOV.PA FAQ
What does NOVACYT do?
Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 234 full-time employees. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. The company offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.
What is the current price of ALNOV stock?
The current stock price of ALNOV.PA is 0.4355 EUR. The price decreased by -1.14% in the last trading session.
What is the dividend status of NOVACYT?
ALNOV.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALNOV stock?
ALNOV.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of NOVACYT (ALNOV.PA)?
NOVACYT (ALNOV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
How many employees does NOVACYT have?
NOVACYT (ALNOV.PA) currently has 240 employees.
Can you provide the market cap for NOVACYT?
NOVACYT (ALNOV.PA) has a market capitalization of 30.76M EUR. This makes ALNOV.PA a Nano Cap stock.
ALNOV.PA Technical Analysis
ALNOV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNOV.PA. ALNOV.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALNOV.PA Financial Highlights
Over the last trailing twelve months ALNOV.PA reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 17.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.32% | ||
| ROE | -74.44% | ||
| Debt/Equity | 0.24 |